(+)-ITD-1 is a resolved enantiomer of ITD-1 that possesses a greater than 2-fold increase in TGF-β inhibition (~400 nM) and 1.3-fold increase in cardiogenesis compared to the racemic ITD-1. (+)-ITD-1 is largely responsible for TGF-β pathway-selective inhibition that inhibits TGF-β activity by selectively degrading the TGF-β2 receptor at the proteosome level. (+)-ITD-1 does not block the closely related Activin A signaling pathway. (+)-ITD-1 has been formulated as a salt to increase stability and improve water solubility (~0.1 mg/mL) for ease of handling. As a salt, ITD-1 is chemically and metabolically stable and can be used to study a wide range of biological questions in cellular processing and TGF-β signaling.

(+)-ITD-1 is a resolved enantiomer of ITD-1 that possesses a greater than 2-fold increase in TGF-β inhibition (~400 nM) and 1.3-fold increase in cardiogenesis compared to the racemic ITD-1. (+)-ITD-1 is largely responsible for TGF-β pathway-selective inhibition that inhibits TGF-β activity by selectively degrading the TGF-β2 receptor at the proteosome level. (+)-ITD-1 does not block the closely related Activin A signaling pathway. (+)-ITD-1 has been formulated as a salt to increase stability and improve water solubility (~0.1 mg/mL) for ease of handling. As a salt, ITD-1 is chemically and metabolically stable and can be used to study a wide range of biological questions in cellular processing and TGF-β signaling.